000286095 001__ 286095
000286095 005__ 20260413131657.0
000286095 0247_ $$2doi$$a10.1016/j.tjpad.2026.100545
000286095 0247_ $$2ISSN$$a2274-5807
000286095 0247_ $$2ISSN$$a2426-0266
000286095 037__ $$aDZNE-2026-00391
000286095 041__ $$aEnglish
000286095 082__ $$a610
000286095 1001_ $$00000-0003-0295-6834$$aBrem, Anna-Katharine$$b0
000286095 245__ $$aScreening for Alzheimer’s disease in the community using an AI-driven screening platform: design of the PREDICTOM study
000286095 260__ $$a[Paris]$$bElsevier Masson SAS$$c2026
000286095 3367_ $$2DRIVER$$aarticle
000286095 3367_ $$2DataCite$$aOutput Types/Journal article
000286095 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1776078888_32198
000286095 3367_ $$2BibTeX$$aARTICLE
000286095 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286095 3367_ $$00$$2EndNote$$aJournal Article
000286095 520__ $$aRecent developments in physiological, imaging and digital biomarkers combined with the approval of new disease-modifying drugs against Alzheimer's disease (AD) and diagnostic blood tests provide an opportunity to shift the first diagnostic steps to the home-setting. While these novel biomarkers enable scalable screening and earlier detection and treatment of AD, they require an evaluation of their accuracy, feasibility, and safety in primary care and the community setting.The aim of PREDICTOM is to develop and test the accuracy of an artificial intelligence (AI) driven screening platform for the risk assessment and early detection of AD to extend the clinical pathway to home-based screening using established and novel biomarkers.PREDICTOM is a European (Norway, UK, Belgium, France, Switzerland, Germany, Spain) observational, prospective cohort study using a cloud-based platform that stores a digitalised journey for each participant and provides a collection of artificial-intelligence (AI) algorithms and tools for risk assessment and early diagnosis and prognosis.Cohort 1 consists of 4000 adults aged 50 years or older at risk of developing AD. Cohort 2 consists of 615 participants selected from Cohort 1 based on estimates indicating high (N = 415) or low (N = 200) risk of AD. Data from existing cohorts will guide the analytic strategy of the study.Cohort 1 will undergo home-based assessments (Level 1), Cohort 2 will undergo in-clinic assessments (Levels 2 and 3). Level 1 includes at-home screening, collecting digital and physiological data (questionnaires, cognition, hearing, eye-tracking) and biofluids (capillary blood via finger-stick and saliva) for biomarker analysis. Level 2 comprises a more complex biomarker collection, most of which can be completed in primary care, including EEG, MRI, venous blood, microbiome from stool, cognition, hearing, and eye-tracking. Level 3 includes a diagnostic evaluation to confirm or rule out AD pathology using established biomarkers (cerebrospinal fluid, or amyloid PET).PREDICTOM will develop AI-driven algorithms for the early detection of AD using biomarkers that can be collected at home or in the community care setting, and evaluate their integration into a well-defined and comprehensive clinical pathway.
000286095 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000286095 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000286095 650_7 $$2Other$$aAlzheimer’s disease
000286095 650_7 $$2Other$$aArtificial intelligence
000286095 650_7 $$2Other$$aBiomarker
000286095 650_7 $$2Other$$aEarly detection
000286095 7001_ $$aKhan, Zunera$$b1
000286095 7001_ $$aRadermacher, Jonas$$b2
000286095 7001_ $$00000-0001-9116-4729$$aGeorgiadis, Kostas$$b3
000286095 7001_ $$aLazarou, Ioulietta$$b4
000286095 7001_ $$00000-0003-1064-9439$$aGrammatikopoulou, Margarita$$b5
000286095 7001_ $$00009-0004-9428-2164$$aPickering, Ellie$$b6
000286095 7001_ $$aMitterreiter, Johanna$$b7
000286095 7001_ $$00000-0001-8459-6240$$aAakre, Jon Arild$$b8
000286095 7001_ $$aAshton, Nicholas J.$$b9
000286095 7001_ $$aBaquero, Miguel$$b10
000286095 7001_ $$00000-0002-0072-5525$$aBeser-Robles, Maria$$b11
000286095 7001_ $$00000-0001-9572-6653$$aBraboszcz, Claire$$b12
000286095 7001_ $$aBrandt, Sigurd$$b13
000286095 7001_ $$aBrown, James$$b14
000286095 7001_ $$00000-0003-2220-0567$$aCacciamani, Federica$$b15
000286095 7001_ $$00000-0002-0269-8751$$aCampill, Sarah$$b16
000286095 7001_ $$00000-0003-2850-1950$$aCollins, Christopher$$b17
000286095 7001_ $$aDeshpande, Pushkar$$b18
000286095 7001_ $$aDiaz, Ana$$b19
000286095 7001_ $$00000-0002-9450-6920$$aDurrleman, Stanley$$b20
000286095 7001_ $$aEngelborghs, Sebastiaan$$b21
000286095 7001_ $$aFerré-González, Laura$$b22
000286095 7001_ $$0P:(DE-2719)9001538$$aFrisoni, Giovani B.$$b23
000286095 7001_ $$00000-0002-8762-3109$$aGjestsen, Martha Therese$$b24
000286095 7001_ $$aGove, Dianne$$b25
000286095 7001_ $$00000-0003-0996-1062$$aHonigberg, Lee$$b26
000286095 7001_ $$aHuang, Bin$$b27
000286095 7001_ $$00009-0009-6294-5345$$aHudak, Anett$$b28
000286095 7001_ $$aKaushik, Sandeep$$b29
000286095 7001_ $$00000-0002-6035-4009$$aLetoha, Tamas$$b30
000286095 7001_ $$aMarquardt, Gaby$$b31
000286095 7001_ $$00000-0002-9497-0707$$aMendes, Augusto J.$$b32
000286095 7001_ $$00000-0003-3947-4695$$aMüllenborn, Matthias$$b33
000286095 7001_ $$00000-0001-5819-2429$$aPaletta, Lucas$$b34
000286095 7001_ $$ade Barros, Nuno Pedrosa$$b35
000286095 7001_ $$aPszeida, Martin$$b36
000286095 7001_ $$00000-0002-5162-3035$$aVik-Mo, Audun Osland$$b37
000286095 7001_ $$aRostamipour, Hossein$$b38
000286095 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b39$$udzne
000286095 7001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris Stephan$$b40$$udzne
000286095 7001_ $$aRussegger, Silvia$$b41
000286095 7001_ $$aSchirmer, Timo$$b42
000286095 7001_ $$aShadmaan, Amied$$b43
000286095 7001_ $$aSolana, Ana Beatriz$$b44
000286095 7001_ $$00000-0002-4704-927X$$aSoria-Frisch, Aureli$$b45
000286095 7001_ $$00000-0002-4701-4309$$aTegethoff, Paulina$$b46
000286095 7001_ $$aRibbens, Annemie$$b47
000286095 7001_ $$aDe Witte, Sara$$b48
000286095 7001_ $$00000-0002-1033-1335$$avan der Giezen, Mark$$b49
000286095 7001_ $$00000-0002-1367-5133$$aNikolopoulos, Spiros$$b50
000286095 7001_ $$00000-0003-2015-0316$$aCorbett, Anne$$b51
000286095 7001_ $$aFröhlich, Holger$$b52
000286095 7001_ $$aAarsland, Dag$$b53
000286095 773__ $$0PERI:(DE-600)2782183-3$$a10.1016/j.tjpad.2026.100545$$gVol. 13, no. 5, p. 100545 -$$n5$$p100545$$tThe journal of prevention of Alzheimer's disease$$v13$$x2274-5807$$y2026
000286095 8564_ $$uhttps://pub.dzne.de/record/286095/files/DZNE-2026-00391.pdf$$yRestricted
000286095 8564_ $$uhttps://pub.dzne.de/record/286095/files/DZNE-2026-00391.pdf?subformat=pdfa$$xpdfa$$yRestricted
000286095 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b39$$kDZNE
000286095 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001808$$aExternal Institute$$b40$$kExtern
000286095 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000286095 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-11$$wger
000286095 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-11$$wger
000286095 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJPAD-J PREV ALZHEIM : 2022$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2025-05-28T09:11:42Z
000286095 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2025-05-28T09:11:42Z
000286095 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2025-05-28T09:11:42Z
000286095 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJPAD-J PREV ALZHEIM : 2022$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-11
000286095 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-11
000286095 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000286095 980__ $$ajournal
000286095 980__ $$aEDITORS
000286095 980__ $$aVDBINPRINT
000286095 980__ $$aI:(DE-2719)5000022
000286095 980__ $$aUNRESTRICTED